Moderna (MRNA) stock is plunging Thursday after the COVID-19 vaccine maker announced plans to slash research and development (R&D) expenses and instead focus on receiving approvals for the many drugs in its pipeline.
Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus to winning approvals for the 10 products in its pipeline.
"Moderna now has five respiratory vaccines with positive Phase 3 results and expects to submit three for approval this year," said Moderna CEO Stéphane Bancel in a statement. "In addition, we have five non-respiratory products in pivotal studies across cancer, rare diseases and latent vaccines with potential for approval by 2027."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Bancel adds that "the size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business."
The shift in strategy comes as Moderna has seen a sharp decline in sales of its COVID-19 vaccine, including a 37% year-over-year decrease in its most recent quarter.
In the release, Moderna also said it anticipates fiscal 2025 revenue to be in the range of $2.5 billion to $3.5 billion and sales to grow at a 25% compound annual growth rate from 2026 to 2028, "driven by new product launches."
The midpoint of MRNA's revenue outlook for its upcoming fiscal year, $3 billion, came in well below analysts' expectations. Wall Street is expecting revenue of $3.74 billion in fiscal 2025, according to Yahoo Finance.
Is Moderna stock a buy, sell or hold?
Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker.
According to S&P Global Market Intelligence, the consensus analyst target price for MRNA stock is $125.71, representing implied upside of more than 90% to current levels. Additionally, the consensus recommendation is Buy. However, analysts may revise their targets lower following the reaction to its updated R&D plans.
And some analysts are already on the sidelines when it comes to the large-cap stock, including financial services firm William Blair, which has a Market Perform rating (equivalent to a Hold) on MRNA.
"Like other biotechnology companies with development pipelines, Moderna's risks center on commercial, regulatory, and clinical development," said William Blair analyst Myles Minter in an August 16 note.
The analyst adds that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show equivalent efficacy across various flu strains versus currently available and other emerging flu vaccines, poor tolerability and/or efficacy with repeat mRNA therapeutics dosing, and other potential clinical setbacks including failed or delayed trials."
Related Content
-
The Most Tax-Friendly State for Retirement in 2025: Here It IsRetirement Tax How do you retire ‘tax-free’? This state doesn’t tax retirement income, has a low median property tax bill, and even offers savings on gas. Are you ready for a move?
-
Plan for Higher Health Care Costs in 2026: Projected Medicare Part B and Part D PremiumsIn 2026, Medicare participants will pay more for their health care. Part B costs are expected to rise more than 10%. Here's what you can do.
-
Avoid Medicare's 'Shadow Tax' With This Financial Expert's IRMAA-Busting TipsYou're cruising along in retirement, and then bam: Your Medicare premiums soar because your income crossed the limit. Take a breath. There could be a solution.
-
Grilling Season and ETFs: There's More Than One Way to Cook Up a PortfolioExchange-traded funds come in a multitude of 'flavors' these days, from passive to active to factor-based. Their flexibility is what makes them so delicious.
-
You Don't Want It, But You Should Plan for It Anyway: An Expert Guide to Long-Term CarePlanning for long-term care is crucial to protect your independence, family and financial stability against unexpected health events and rising care costs not covered by standard insurance.
-
Japan Tariffs: 5 Things That Might Get More Expensive for YouPresident Donald Trump's trade agreement with Japan features a 15% reciprocal tariff for all imported products, which could impact the prices of these items when you go shopping.
-
Five Questions to Help Ensure a Happy, Secure RetirementYou need to drill down to what you really want out of retirement. Then you can get down to the business of crafting a financial plan to make it happen.
-
I'm a Financial Adviser: This Is How You Can Save for Big Goals Even if You Feel Like You're Barely Getting ByLearning good financial habits — building an emergency fund, paying down debt, saving consistently — gives you flexibility, options and a path to security.
-
How to Buy an Annuity Online (Without Regret)You should never be rushed into buying an annuity. But now that they can be sold quickly and easily online, you need to be more alert than ever to pushy salesmanship. Here are four signs you're working online with a professional.
-
Dow Dives 542 Points on Soft Jobs Data: Stock Market TodayThe last day of a busy week ends with the first greater-than-1% move in either direction in more than a month.
